EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Human toll-like receptor 8 (TLR8) in NK cells: Implication for cancer immunotherapy

Irene Veneziani, Claudia Alicata, Lorenzo Moretta, Enrico Maggi

Immunology Letters · 2023

DOI: 10.1016/j.imlet.2023.07.003 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Immunology Letters, 2023. Verfasst von Irene Veneziani und 3 weiteren Autor:innen. Beteiligte Einrichtung: Tumor Immunology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy. Hauptthemen laut MEDLINE: Toll-Like Receptor 8, Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fondazione Italiana per la Ricerca sul Cancro, Ministero della Salute, Fondazione Umberto Veronesi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Toll-like receptors (TLR)s are homo- or heterodimeric proteins, whose structure and function were widely described in the antigen presenting cells (APC), such as Dendritic cells (DC). Recently, the expression and the role of TLRs in fighting against pathogens, was described also in NK cells. Their activation and functional properties can be directly and indirectly modulated by agonists for TLRs. In particular CD56bright NK cells subset, that is the most abundant NK cell subset in tissues and tumor microenvironment (TME), was mostly activated in terms of pro-inflammatory cytokine production, proliferation and cytotoxicity, by agonists specific for endosomal TLR8. The interplay between DC and NK, that depends on both cell-to-cell contact and soluble factors such as cytokines, promote both DC maturation and NK cell activation. Based on this concept, a TLR based immunotherapy aimed to activate NK-DC axis, may modulate TME by inducing a pro-inflammatory phenotype, thus improving DC ability to present tumor-associated antigens to T cells, and NK cell cytotoxicity against tumor cells. In this mini-review, we report data of recent literature about TLRs on human NK cells and their application as adjuvant in cancer vaccines or in combined tumor immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Toll-Like Receptor 8NeoplasmsHumansToll-Like ReceptorsKiller Cells, NaturalImmunotherapyDendritic CellsToll-Like Receptor 7Tumor Microenvironment

Stichwörter der Autor:innen

AdjuvantsEndosomal toll like receptorsNK cells subsetsToll like receptors agonistsTumor immunotherapy

Substanzen

Toll-Like Receptor 8Toll-Like ReceptorsToll-Like Receptor 7TLR8 protein, human

Autor:innen und Institutionen

  • Tumor Immunology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
  • Tumor Immunology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy. Electronic address: Lorenzo.moretta@opbg.net.

Förderung

  • Fondazione Italiana per la Ricerca sul Cancro
  • Ministero della Salute
  • Fondazione Umberto Veronesi
  • Associazione Italiana per la Ricerca sul Cancro

Zitieren

APA

Veneziani, I., Alicata, C., Moretta, L., & Maggi, E. (2023). Human toll-like receptor 8 (TLR8) in NK cells: Implication for cancer immunotherapy. Immunology Letters. https://doi.org/10.1016/j.imlet.2023.07.003

Vancouver

Veneziani I, Alicata C, Moretta L, Maggi E. Human toll-like receptor 8 (TLR8) in NK cells: Implication for cancer immunotherapy. Immunology Letters. 2023. doi:10.1016/j.imlet.2023.07.003

BibTeX
@article{Veneziani2023,
  author = {Veneziani, Irene and Alicata, Claudia and Moretta, Lorenzo and Maggi, Enrico},
  title = {Human toll-like receptor 8 (TLR8) in NK cells: Implication for cancer immunotherapy},
  journal = {Immunology Letters},
  year = {2023},
  doi = {10.1016/j.imlet.2023.07.003}
}
Kostenlos starten →